CardioKinetix has developed a novel transcatheter implant called Parachute Ventricular Partitioning Device, which already received the CE mark and has now won approval for two additional sizes. The Parachute is a partitioning membrane deployed within the compromised ventricle that is intended to treat heart failure resulting from myocardial infarction.
The Parachute consists of a synthetic fluoropolymer (ePTFE) membrane stretched over a nitinol frame. The idea behind the device is that it partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, which decreases the overall volume and restores a more normal geometry and function in the left ventricle.
Early trials have shown the Parachute to decrease heart failure symptoms and increase exercise capacity and quality of life, with additional trials underway. If indeed proven effective, this could be an important addition to the interventional cardiologist’s toolbox.
Product page: CardioKinetix Parachute…